文献速递生殖医学

促性腺激素刺激IUI周期中优势卵泡大小与临床妊娠的关联

Association between leading follicle size and clinical pregnancy in gonadotropin-stimulated intrauterine insemination cycles with human chorionic gonadotropin trigger: a retrospective cohort study.
PubMed 文献 · Fertil Steril · 2026-08-07

该回顾性队列研究纳入516名女性共801个促性腺激素刺激联合hCG扳机的IUI周期,分析扳机日优势卵泡大小与临床妊娠率的关系。主要模型显示调整后预测临床妊娠率在约16 mm达峰,超过17 mm后下降;19-21 mm组临床妊娠率6.1%,低于15-16 mm组的16.5%。

要点

  • 扳机日优势卵泡15-16 mm时临床妊娠率最高,约16 mm达峰值。
  • 优势卵泡超过17 mm与调整后临床妊娠概率降低相关,19-21 mm组风险比显著下降。
  • 该结果可为促性腺激素刺激IUI周期的扳机时机优化提供参考依据。

核心结论

  • 促性腺激素刺激联合hCG扳机的IUI周期中,优势卵泡15-16 mm为临床妊娠的较优范围。
  • 优势卵泡超过17 mm与调整后临床妊娠概率降低相关。

研究设计与样本

  • 回顾性队列研究,纳入2019年1月至2025年12月间516名排卵功能障碍或不明原因不孕女性的801个促性腺激素刺激、hCG扳机IUI周期。
  • 主要分析采用以女性为聚类稳健标准误的改良Poisson回归模型中的自然立方样条连续建模优势卵泡大小。

主要发现

  • 15-16 mm、17-18 mm和19-21 mm组的临床妊娠率分别为16.5%(55/334)、12.5%(48/385)和6.1%(5/82)。
  • 以16 mm为参照,18 mm的调整风险比为0.66(95%CI 0.47-0.92),19 mm为0.42(95%CI 0.22-0.81),20 mm为0.27(95%CI 0.10-0.75)。
  • 19-21 mm组较15-16 mm组的调整风险比为0.35(95%CI 0.14-0.84),卵泡>17 mm较≤17 mm的调整风险比为0.62(95%CI 0.40-0.97)。

关键数值与推荐

  • 临床妊娠率为主要结局指标。
  • 样条模型显示调整后预测临床妊娠率在约16 mm达峰,超过17 mm后下降。
  • 仅首周期样条模型和广义可加模型敏感性分析均支持约17 mm后呈相似下降趋势。

临床怎么用

  • 在促性腺激素刺激联合hCG扳机的IUI周期中,可考虑将优势卵泡15-16 mm作为扳机时机的参考范围。
  • 优势卵泡超过17 mm时临床妊娠概率可能降低,应结合个体情况综合评估扳机决策。

局限性

  • 本研究为回顾性队列设计,可能存在未测量混杂因素。
  • 原文摘要未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the association between the leading follicle size on the day of human chorionic gonadotropin (hCG) trigger and clinical pregnancy in gonadotropin-stimulated intrauterine insemination (IUI) cycles. DESIGN: Retrospective cohort study. SUBJECTS: Women with ovulatory dysfunction or unexplained infertility undergoing gonadotropin-stimulated, hCG-triggered IUI cycles. EXPOSURE: Ovarian stimulation with gonadotropins, hCG trigger, and IUI. MAIN OUTCOME MEASURES: Clinical pregnancy rate (CPR) was the primary outcome. The primary analysis modeled leading follicle size continuously using a natural cubic spline within a modified Poisson regression model with robust standard errors clustered by woman. Secondary analyses used categorical modified Poisson models, and sensitivity analyses included a spline model of first-cycle-only and an adjusted generalized additive model. RESULTS: A total of 516 women with 801 gonadotropin-stimulated IUI cycles between January 2019 and December 2025 were included. The CPRs were 16.5% (55/334), 12.5% (48/385), and 6.1% (5/82) for leading follicle sizes of 15-16 mm, 17-18 mm, and 19-21 mm, respectively. In the primary spline-based model, adjusted predicted CPR peaked at approximately 16 mm and declined beyond 17 mm. Compared with 16 mm, the adjusted risk ratio (aRR) was significantly lower at 18 mm (aRR 0.66; 95% confidence interval [CI] 0.47-0.92), 19 mm (aRR 0.42; 95% CI 0.22-0.81), and 20 mm (aRR 0.27; 95% CI 0.10-0.75). Modified Poisson regression supported this pattern, showing lower adjusted CPR in the 19-21 mm group vs. 15-16 mm (aRR 0.35; 95% CI 0.14-0.84) and for follicle size >17 mm vs. ≤17 mm (aRR 0.62; 95% CI 0.40-0.97). First-cycle-only spline model and generalized additive model sensitivity analyses supported a similar downward trend beyond approximately 17 mm. CONCLUSION: A leading follicle size of 15-16 mm appears to be the optimal range for clinical pregnancy in gonadotropin-stimulated, hCG-triggered IUI cycles, whereas leading follicles >17 mm were associated with a lower adjusted clinical pregnancy probability. These findings provide evidence-based guidance for optimizing gonadotropin-IUI treatments.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Ngo VDT, Pham YTB, Le KD, et al. Association between leading follicle size and clinical pregnancy in gonadotropin-stimulated intrauterine insemination cycles with human chorionic gonadotropin trigger: a retrospective cohort study. Fertil Steril. 2026. PMID: 42567469. doi:10.1016/j.fertnstert.2026.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。